How To Progress Safe and Effective Cell Therapies for Clinical Use

Sistemic believe cell characterisation is an essential element in progressing safe and effective cell therapies for mainstream clinical use. They offer unique miRNA analytical services that provide reliable and costeffective, characterisation and QC tools that are applicable to all cell systems. Toward this end, Dr Vincent O’Brien (Chief Scientific Officer) and Dr Verna McErlane (Director of Commercial Operations, International)  presented data supporting the utility of miRNA in the provision of  superior cell characterisation and QC methods at the Stem Cells Europe conference in July.

Dr Vincent O’Brien presented a poster entitled ‘A novel microRNA-based stem cell characterisation and monitoring tool’, and Verna McErlane joined: Marilyn Robertson, SSCN; Aidan Courtney, Roslin Cells; Dr David Hay, Fibromed; and Michael Leek, Immunosolv, at the Scottish Stem Cell Network (SSCN) Panel showcase, ‘Progress to Therapy and Market’. Sistemic Ltd are a global company offering unique miRNA-based products and services such as  SistemQCTM, designed for the sophisticated  molecular characterisation of cells, which combines robust miRNA profiling, statistical analysis and contextual analysis.